<DOC>
	<DOC>NCT01242514</DOC>
	<brief_summary>The purpose of this study is to evaluate the long term safety and tolerability of fostamatinib in patients with rheumatoid arthritis (RA).</brief_summary>
	<brief_title>Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Patients who have successfully completed a qualifying study (D4300C00001, D4300C00002, D4300C00003 or D4300C00004) with fostamatinib Patients who have participated in a qualifying study and who have been classified as nonresponders due to predefined lack of efficacy at Week 12 (D4300C00001, D4300C00002, D4300C00003). Premature withdrawal from the qualifying study (D4300C00001, D4300C00002, D4300C00003 and D4300C00004) Females who are pregnant or breast feeding Poorly controlled hypertension Significant liver function test abnormalities or physical symptoms of hepatotoxicity Significant infection Gastrointestinal intolerance Cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>OSKIRA</keyword>
	<keyword>Fostamatinib</keyword>
</DOC>